Neon Therapeutics (NTGN) annual income statement covering fiscal 2016 through 2019, as reported to the SEC.
An income statement shows what a company sold and what it cost to run the business, ending with the profit left over.
| Dec'19 | Dec'18 | Dec'17 | Dec'16 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating expenses: | |||||||||||||||||||
Research and development | |||||||||||||||||||
59,718 | 60,425 | 37,195 | 19,673 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Research and development | 59,718 | 60,425 | 37,195 | 19,673 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
General and administrative | |||||||||||||||||||
21,420 | 18,276 | 10,892 | 7,749 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
General and administrative | 21,420 | 18,276 | 10,892 | 7,749 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Total operating expenses | |||||||||||||||||||
81,138 | 78,701 | 48,087 | 27,422 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Total operating expenses | 81,138 | 78,701 | 48,087 | 27,422 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Loss from operations | |||||||||||||||||||
-81,138 | -78,701 | -48,087 | -27,422 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Loss from operations | -81,138 | -78,701 | -48,087 | -27,422 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Other income (expense), net | |||||||||||||||||||
Interest income | |||||||||||||||||||
1,401 | 1,792 | 569 | - | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Interest income | 1,401 | 1,792 | 569 | - | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Other expense | |||||||||||||||||||
39 | 25 | 18 | 11 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Other expense | 39 | 25 | 18 | 11 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Total other income (expense), net | |||||||||||||||||||
1,362 | 1,767 | 551 | -11 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Total other income (expense), net | 1,362 | 1,767 | 551 | -11 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Net Income (Loss) Attributable to Parent | |||||||||||||||||||
-79,776 | -76,934 | -47,536 | -27,433 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Net Income (Loss) Attributable to Parent | -79,776 | -76,934 | -47,536 | -27,433 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Temporary Equity, Accretion to Redemption Value, Adjustment | |||||||||||||||||||
- | 6,371 | 10,396 | 2,989 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Temporary Equity, Accretion to Redemption Value, Adjustment | - | 6,371 | 10,396 | 2,989 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Net loss attributable to common stockholders | |||||||||||||||||||
-79,776 | -83,305 | -57,932 | -30,422 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Net loss attributable to common stockholders | -79,776 | -83,305 | -57,932 | -30,422 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Net loss per share, basic and diluted (in dollars per share) | |||||||||||||||||||
-2.86 | -5.54 | -34.32 | -30.72 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Net loss per share, basic and diluted (in dollars per share) | -2.86 | -5.54 | -34.32 | -30.72 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Weighted average common shares outstanding, basic and diluted (in shares) | |||||||||||||||||||
27,878 | 15,036 | 1,687 | 990 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Weighted average common shares outstanding, basic and diluted (in shares) | 27,878 | 15,036 | 1,687 | 990 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Comprehensive loss: | |||||||||||||||||||
Net Income (Loss) Attributable to Parent | |||||||||||||||||||
-79,776 | -76,934 | -47,536 | -27,433 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Net Income (Loss) Attributable to Parent | -79,776 | -76,934 | -47,536 | -27,433 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Other comprehensive income: | |||||||||||||||||||
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent | |||||||||||||||||||
75 | -62 | -13 | - | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent | 75 | -62 | -13 | - | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Total other comprehensive income | |||||||||||||||||||
75 | -62 | -13 | - | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Total other comprehensive income | 75 | -62 | -13 | - | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||
Comprehensive loss | |||||||||||||||||||
-79,701 | -76,996 | -47,549 | -27,433 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | ||||||
Comprehensive loss | -79,701 | -76,996 | -47,549 | -27,433 | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | xxxxx | |||||